By Fineline Cube Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Inc. has received clinical trial approval from China’s National Medical Products Administration (NMPA) for GenSci144, a Category 1 chemical drug designated for the treatment of phenylketonuria (PKU).
Regulatory Milestone
| Parameter | Detail |
|---|---|
| Parent Company | Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) |
| Subsidiary | Changchun GeneScience Pharmaceutical Inc. |
| Drug Candidate | GenSci144 (Category 1 chemical drug) |
| Regulatory Authority | National Medical Products Administration (NMPA) |
| Approval Type | Clinical trial approval granted |
| Indication | Phenylketonuria (PKU) |
Disease Background & Unmet Need
Phenylketonuria (PKU) Overview
- Genetic Basis: Autosomal recessive disorder caused by PAH gene defects
- Pathophysiology: Deficiency in phenylalanine hydroxylase (PAH) activity leading to impaired phenylalanine metabolism
- Clinical Consequence: Hyperphenylalaninemia (HPA) – elevated blood phenylalanine levels causing neurological damage if untreated
- Current Treatment Limitations: Existing therapies depend on residual PAH enzyme activity, excluding many severe PKU patients
GenSci144 Mechanism of Action
- Molecule Type: Oral small-molecule inhibitor
- Target: Neutral amino acid transporter SLC6A19
- Primary Mechanism: Inhibits SLC6A19-mediated renal tubular reabsorption of phenylalanine
- Therapeutic Effect: Reduces blood phenylalanine levels through enhanced urinary excretion
- Key Innovation: Independent of residual PAH enzyme activity, potentially applicable to broader PKU patient population
- Combination Potential: Compatible with existing treatment regimens for synergistic effect
Strategic Advantages & Market Opportunity
Patient Population Expansion
- Broader Applicability: Treats patients regardless of PAH mutation severity or residual enzyme function
- Severe PKU Coverage: Addresses previously untreatable patient subpopulations
- Pediatric Focus: Potential for early intervention to prevent neurological complications
Commercial Differentiation
- Oral Administration: Superior convenience compared to injectable or dietary restriction approaches
- Novel Target: First-in-class approach targeting renal phenylalanine handling rather than hepatic metabolism
- Category 1 Status: Highest innovation classification in China’s regulatory framework
Market Context
- Global PKU Prevalence: Approximately 1 in 10,000-15,000 live births worldwide
- China Patient Population: Estimated 15,000-20,000 PKU patients requiring lifelong treatment
- Treatment Gap: Significant unmet need for effective therapies in severe and non-responsive cases
- Pricing Premium: Novel mechanism and broad applicability support premium pricing strategy
Development Pathway & Timeline
- Current Stage: IND approval granted – Phase I studies expected to initiate Q3-Q4 2026
- Clinical Strategy: Initial safety and pharmacokinetic studies followed by proof-of-concept in PKU patients
- Regulatory Path: Potential accelerated approval pathway given orphan disease designation and Category 1 status
- International Potential: Platform technology may support global development following Chinese validation
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market expectations for GenSci144. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market access challenges.-Fineline Info & Tech